1 Departments of Pediatrics, 5 Environmental Medicine, and 6 Chemical Engineering, University of Rochester, Rochester 14642; 3 Departments of Pediatrics and 4 Obstetrics and Gynecology, State University of New York at Buffalo, Buffalo, New York 14214; and 2 Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina 29425
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The content-dependent
activity of surfactant protein (SP)-B was studied in mixtures with
dipalmitoyl phosphatidylcholine (DPPC), synthetic lipids (SL), and
purified phospholipids (PPL) from calf lung surfactant extract (CLSE).
At fixed SP-B content, adsorption and dynamic surface tension lowering
were ordered as PPL/SP-B SL/SP-B > DPPC/SP-B. All
mixtures were similar in having increased surface activity as SP-B
content was incrementally raised from 0.05 to 0.75% by weight. SP-B
had small but measurable effects on interfacial properties even at very
low levels
0.1% by weight. PPL/SP-B (0.75%) had the highest
adsorption and dynamic surface activity, approaching the behavior of
CLSE. All mixtures containing 0.75% SP-B reached minimum surface
tensions <1 mN/m in pulsating bubble studies at low phospholipid
concentration (1 mg/ml). Mixtures of PPL or SL with SP-B (0.5%) also
had minimum surface tensions <1 mN/m at 1 mg/ml, whereas DPPC/SP-B
(0.5%) reached <1 mN/m at 2.5 mg/ml. Physiological activity also was
strongly dependent on SP-B content. The ability of instilled SL/SP-B
mixtures to improve surfactant-deficient pressure-volume mechanics in
excised lavaged rat lungs increased as SP-B content was raised from 0.1 to 0.75% by weight. This study emphasizes the crucial functional activity of SP-B in lung surfactants. Significant differences in SP-B
content between exogenous surfactants used to treat respiratory disease
could be associated with substantial activity variations.
surfactant proteins; lung surfactant; exogenous surfactants; calf lung surfactant extract
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
ENDOGENOUS PULMONARY SURFACTANT is a complex mixture of lipids and three biophysically active proteins: surfactant protein (SP)-A, SP-B, and SP-C. The physiological necessity of surfactant in respiratory function has led to extensive research on the biophysics, cell and molecular biology, and physiology of this complex material (11, 20, 34, 38). Although lipids (primarily phospholipids) comprise the great majority of lung surfactant in a quantitative sense, the apoprotein constituents of the surfactant system are highly active and crucial in a functional sense. This is also the case in most of the exogenous surfactant preparations used in the therapy of the neonatal and acute respiratory distress syndromes. The hydrophobic surfactant proteins SP-B and SP-C both have strong molecular interactions with lipids. Because of its combination of polar and nonpolar residues and overall amphipathic structure, SP-B can interact with both phospholipid head groups and fatty chains and is particularly active in enhancing surface active behavior in endogenous and exogenous lung surfactants (13, 25, 34, 44, 46, 48, 56, 58). However, the content-dependent effects of SP-B on the surface and physiological activity of lipids have not been fully quantitated.
A better understanding of SP-B's content-dependent actions in mixtures
with lipids is directly relevant for the function of animal-derived
clinical exogenous surfactants, which vary significantly in their
compositional levels of this apoprotein (4, 19, 39, 47).
The present study examines the effects of ascending amounts of bovine
SP-B in increasing the adsorption and dynamic surface activity of 1,2 dipalmitoyl-sn-3-phosphocholine (DPPC), mixed synthetic
lipids (SL), and purified surfactant phospholipids (PPL) isolated by
gel permeation chromatography from calf lung surfactant extract (CLSE).
Adsorption is measured in an apparatus with a stirred subphase to
remove diffusion resistance, and dynamic surface tension lowering is
assessed during cycling at rapid physiological rates in a pulsating
bubble surfactometer. Surface pressure-area (-A) isotherms and
dynamic respreading are also defined for solvent-spread phospholipid-SP-B films at the air-water interface in a Wilhelmy surface balance. In addition to surfactant biophysical studies, the
content-dependent activity of SP-B combined with synthetic lipids is
examined in a well-characterized excised rat lung model used in the
quality control manufacture of several Food and Drug Administration-approved clinical exogenous surfactants (Survanta, Infasurf) (3). Biophysical and excised lung experiments
are used to study the activity of SP-B contents incrementally varying from 0.05 to 0.75% by weight in mixtures with lipids.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Synthetic phospholipids and lipids. Synthetic DPPC, egg phosphatidylcholine (egg PC), egg phosphatidylglycerol (egg PG), egg phosphatidylinositol (egg PI), egg phosphatidylethanolamine (egg PE), and bovine brain sphingomyelin (Sph) for activity studies were purchased from Avanti Polar Lipids (Alabaster, AL). Cholesterol was reagent grade from Sigma (St. Louis, MO). DPPC was >99% pure as supplied and gave a single well-defined spot on thin-layer chromatography with solvent system C of Touchstone et al. (51). Egg PC, egg PG, egg PI, egg PE, and Sph gave broader single spots on thin-layer analysis, consistent with their content of multiple fatty chain derivatives. Activity experiments utilized either pure DPPC or SL, the latter roughly based on the lipid composition of lavaged lung surfactant (SL = 40:40:10:5:2.5:2.5 molar ratio DPPC/egg PC/egg PG/egg PI/egg PE/Sph + 5% cholesterol).
CLSE and PPL. Mixed phospholipids were isolated by gel permeation chromatography from solvent-extracted, lavaged calf lung surfactant (18). Intact lungs from freshly killed calves (Gold Medal Packing, Rome, NY) were lavaged with 2-3 l of cold 0.15 M NaCl. Lavage fluid was immediately centrifuged at 12,000 g to obtain whole surfactant, which was then extracted with chloroform-methanol (5) to obtain CLSE. The composition of CLSE by weight was 93% phospholipid, 4.5% cholesterol, 1.5% protein (a mixture of SP-B and SP-C), and 1% other. The phospholipid class distribution was ~85% PC, 5% PG, 4% PI (including phosphatidylserine), 3% PE, 1% Sph, and 2% other (51). ELISA testing using a monoclonal antibody to bovine SP-B (rabbit derived) has reported a level of 0.9% SP-B by weight relative to phospholipid in CLSE material similar to that used here (39). Mixed lung surfactant phospholipids (PPL) were isolated from CLSE by column chromatography with an elution solvent of 1:1 (vol/vol) chloroform-methanol plus 5% 0.1 N HCl (18). Two passes through a Sephadex LH-20 column (Pharmacia-LKB Biotechnology, Piscataway, NJ) separated phospholipids away from hydrophobic surfactant apoproteins and neutral lipids. Acid remaining in PPL fractions was removed by a second chloroform-methanol extraction. Final PPL fractions had a protein content below the limits of detection of both the Folin-phenol reagent assay of Lowry et al. (27) and the amido black assay of Kaplin and Pedersen (26) modified by the addition of 5-15% sodium dodecyl sulfate (SDS).
Purified SP-B. SP-B was purified from CLSE on a 450-ml Silica C8 column with 7:1:0.4 methanol-chloroform-0.1 N HCl or 7:1:0.4 methanol-chloroform-H2O + 0.1% trifluoroacetic acid as elution solvents. Eluted fractions from the first and second column passes were screened by an ultraviolet detector (Pharmacia Biotech, Uppsala, Sweden) at 254 nm, and final pooled SP-B isolates were analyzed by SDS polyacrylamide gel electrophoresis (SDS-PAGE) and NH2-terminal amino acid analysis. Fractions for SDS-PAGE were dried, resuspended in NuPage sample buffer (Novex, San Diego, CA), and applied to 4-10% gradient acrylamide NuPage gels. Electrophoresis was at 200 V for 40 min with a 2-(N-morpholino)ethanesulfonic acid buffer (MES; Novex) containing (in mM) 50 MES, 50 Tris base, 3.5 SDS, and 1 EDTA, pH 7.7. Silver staining for detection of protein bands was according to Morrissey (29). NH2-terminal sequence analysis (7 cycles) was done with an Applied Biosystems Procise amino acid analyzer (pure SP-B yielded a single sequence of Phe-Pro-Ile-Pro-Ile-Pro-Tyr). SP-B fractions were also analyzed by Western blots using rabbit anti-bovine SP-B antibody. Proteins for Western blots were transferred from gels to 0.22-µm nitrocellulose using a Novex electrotransfer unit with current preset at 3 mA/cm2 and a 60-min transfer time. After transfer, the nitrocellulose was blocked in 25 mM Tris base buffer, pH 7.7, containing 0.05% vol/vol Tween 20 and 5% wt/vol nonfat dry milk (Blotto), followed by three 15-min washes with 25 mM Tris base and 0.05% Tween 20, pH 7.7. The nitrocellulose was then incubated in primary polyclonal antibody (rabbit anti-bovine SP-B antibody) in Blotto (1:10,000 dilution) for 60 min, washed several times with Tris-Tween buffer, incubated for 30 min with goat anti-rabbit IgG conjugated to horseradish peroxidase (1:2,500 dilution; Santa Cruz Biotechnology, Santa Cruz, CA), washed with 25 mM Tris base (pH 7.7), and incubated with Luminol reagent (Santa Cruz Biotechnology) for 60 s followed by removal of excess reagent and film development.
Lipid-SP-B mixture formulation. DPPC, PPL, or SL were combined with SP-B as follows. Appropriate amounts of lipids dissolved in chloroform were initially mixed with SP-B in chloroform-methanol and evaporated to dryness under nitrogen. Amounts of phospholipid were determined by phosphate assay (7), and levels of SP-B protein were based on the Folin-phenol reagent assay of Lowry et al. (27) modified by the addition of 15% SDS. Dried lipid-SP-B mixtures were redissolved in 9:1 vol/vol hexane-ethanol (HPLC grade) for Wilhelmy balance film studies or were dispersed at desired concentrations in buffered saline (10 mM HEPES, 1.5 mM CaCl2, 150 mM NaCl, pH 7.0) by probe sonication for adsorption, pulsating bubble, or excised lung studies. Dispersion was with a Heat Systems sonicator (model W-220F) at 40 W of power applied for three to five 15-s bursts on ice. Highly pure distilled and deionized water (Milli-Q UV Plus system; Millipore, Bedford, MA) was used in all dispersions.
Adsorption methods. Adsorption was measured at 37 ± 0.5°C for surfactant dispersions in a Teflon dish containing a 35-ml buffered subphase (10 mM HEPES, 1.5 mM CaCl2, 150 mM NaCl, pH 7.0) (33, 35). The subphase was agitated continuously by a Teflon-coated bar and magnetic stirrer to minimize diffusion resistance. At time zero, a bolus of surfactant dispersion (2.5 mg phospholipid/5 ml buffer) was injected into the stirred subphase, and surface pressure (surface tension lowering below that of the pure subphase) was measured as a function of time by a sandblasted platinum slide connected to a force transducer. Final subphase concentration for adsorption studies was uniform at 0.063 mg phospholipid/ml (2.5 mg/40 ml of total subphase).
Pulsating bubble surfactometer methods. The ability of surfactant mixtures to lower surface tension during rapid cycling at 37°C was measured using a pulsating bubble surfactometer (General Transco, Largo, FL; formerly Electronetics, Amherst, NY) (15). An air bubble, communicating with ambient air, was formed in a buffered suspension of surfactant held in a 40-µl plastic sample chamber. The sample chamber was mounted on the instrument pulsator unit, and the bubble was repetitively oscillated between maximum and minimum radii of 0.55 and 0.4 mm at a rate of 20 complete cycles of compression-expansion per minute. The pressure drop across the air-water interface was measured by a precision pressure transducer. Surface tension at minimum bubble radius (minimum surface tension) was calculated as a function of time from the spherical form of the Laplace equation (16). Surfactant dispersions were studied in the pulsating bubble apparatus at concentrations of both 1 and 2.5 mg phospholipid/ml to increase the sensitivity of measurements to discern the relative activity of the different mixtures studied.
Wilhelmy balance methods.
-A isotherms were measured for solvent-spread interfacial films in a
modified Wilhelmy surface balance incorporating a Teflon trough and
ribbon barrier (49). Surfactants dissolved in
hexane-ethanol (9:1, vol/vol) were spread dropwise from a syringe at
the surface of a buffered subphase (10 mM HEPES, 1.5 mM
CaCl2, 150 mM NaCl, pH 7.0) in the balance trough.
Surfactant films were spread to a uniform initial "surface excess"
concentration of 15 Å2/molecule to examine film behavior
during dynamic cycling in the collapse regime. Typical volumes of
spreading solvent were 0.4 ml, with a 10-min pause allowed for solvent
evaporation before dynamic cycling. Surface pressure
(the amount by
which surface tension was lowered below that of the pure subphase) was
measured during cycling from the force on a sand-blasted platinum
Wilhelmy slide dipped into the ribbon-confined interface. A second
slide outside the ribbon barrier assessed film leakage, which was
absent in all isotherm data reported. Cycling was between maximum and minimum areas of 448 and 103 cm2 (compression ratio 4.35:1)
at 5 min per cycle at 23 ± 1°C. Respreading of molecules
squeezed out of the interfacial film during compression was assessed
from collapse plateaus on the
-A compression curves for
cycles 1, 2, and 7, as defined previously
by Notter and co-workers (34, 37, 57). A value of
zero for the ratio of compression isotherm collapse plateaus on
cycle 2/ cycle 1 or cycle 7/cycle 1 indicated
no respreading between the designated compressions, whereas a collapse
plateau ratio of one indicated complete respreading of film material.
Excised lung pressure-volume methods.
Physiological activity was determined by measuring quasistatic
pressure-volume (P-V) deflation mechanics in an excised rat lung model
at 37°C (3). The thermodynamic consistency of P-V measurements in this model has been documented in multiple studies (see
Ref. 34 for review). Adult Sprague-Dawley male rats
(400-550 g; Charles River, Wilmington, MA) were given a lethal
intraperitoneal bolus of pentobarbital sodium, and lungs were excised
and degassed under vacuum. The lungs were attached to an artificial
trachea in an environmental chamber and rapidly inflated with air
(Harvard small animal respirator, 24.7 ml/min). Inflation was to 30 cmH2O, followed by a 10-15 min period of stress
relaxation to standardize total lung capacity (TLC) and rule out air
leakage. The lungs were then deflated from TLC at a slow rate of 2.47 ml/min to define normal surfactant-sufficient P-V mechanics. Endogenous
surfactant was removed by 15 lavages with cool 0.15 M NaCl, followed by
degassing, reinflation to 30 cmH2O, stress relaxation, and
a second deflation curve to define the surfactant-deficient state. A
surfactant mixture in 0.15 M NaCl was then instilled via the trachea at
a uniform total dose of 100 mg phospholipid/kg rat body wt, and a third P-V deflation curve was measured with identical methods to determine the degree of restoration of mechanics toward normal. The concentration of instilled surfactant mixtures was constant at 25 mg/ml.
Percent volume recovery at selected transpulmonary pressures was
calculated as 100(Vsurf Vdef)/(Vnorm
Vdef), where
Vnorm is the volume of the freshly excised
surfactant-sufficient lungs, Vdef is the volume of the
lavaged surfactant-deficient lungs, and Vsurf is the volume
after surfactant instillation at the pressure of interest.
Statistical analyses. All results are expressed as means ± SE. Statistical analyses used the Student's t-test for comparisons of discrete data points, and functional data were analyzed by one-way analysis of variance with Scheffé's procedure identifying points of significant difference. Differences were considered statistically significant if the probability of the null hypothesis was <0.05.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The adsorption of mixtures of DPPC/SP-B, SL/SP-B, and PPL/SP-B at
37°C is shown in Fig. 1,
A-C, respectively. At fixed SP-B content, the rate of
adsorption was generally most rapid for mixtures containing PPL and SL,
followed by DPPC. However, the variation of adsorption as a function of
SP-B content was very similar in all three sets of mixtures. Very low
amounts of SP-B (0.1% by weight) had a measurable effect in
improving adsorption relative to lipids alone. However, the rate and
magnitude of adsorption increased continuously as the weight percentage
of SP-B was incrementally raised up to 0.75%. PPL/SP-B containing
0.75% apoprotein by weight reached equilibrium surface pressures of
48.5 ± 0.5 mN/m (surface tensions of just under 22 mN/m) after 20 min of adsorption (Fig. 1C). CLSE, which contains
all the components in PPL/SP-B plus cholesterol and SP-C, reached the
same final equilibrium adsorption surface pressure but at a faster rate
(Fig. 1C). Mixtures of SL/SP-B (0.75%) and DPPC/SP-B
(0.75%) reached slightly lower final adsorption surface pressures than
PPL/SP-B (0.75%). Mixtures of lipids with 0.5% SP-B by weight
adsorbed less rapidly than corresponding mixtures containing 0.75%
SP-B. However, final surface pressures for mixtures containing 0.5%
SP-B were only slightly lower than for those containing 0.75% SP-B
(Fig. 1, A-C).
|
The surface tension lowering of mixtures of DPPC/SP-B, SL/SP-B, and
PPL/SP-B during dynamic compression in pulsating bubble experiments is shown in Figs.
2-4. The pattern of activity in
these dynamic studies also showed successive improvements as the
content of SP-B was raised from 0.05 to 0.75% by weight relative to
phospholipid. As in the adsorption results above, overall dynamic
surface activity was generally ordered as PPL/SP-B SL/SP-B > DPPC/SP-B in terms of the time course and/or magnitude
of surface tension lowering. This order of dynamic surface activity was
found at both phospholipid concentrations studied (1 and 2.5 mg/ml).
PPL/SP-B mixtures containing 0.75% by weight of apoprotein to
phospholipid reached minimum surface tensions <1 mN/m almost as
rapidly as CLSE at a low phospholipid concentration of 1 mg/ml (Fig.
4A). Mixtures of SL or DPPC with 0.75%
SP-B also reached very low minimum surface tensions <1 mN/m at 1 mg
phospholipid/ml (Figs. 2A, 3A). Minimum surface
tension values <1 mN/m were also attained by mixtures of PPL/SP-B
(0.5%) and SL/SP-B (0.5%) at a phospholipid concentration of 1 mg/ml, and by DPPC/SP-B (0.5%) at a higher phospholipid concentration of 2.5 mg/ml (Figs. 2-4).
|
|
|
In addition to investigating surface activity in dispersed
phospholipid/SP-B mixtures, apoprotein effects were also studied directly in spread interfacial films in the Wilhelmy balance. In
particular, dynamic respreading during cycling was examined in films of
DPPC/SP-B and PPL/SP-B spread to an initial surface concentration of 15 Å2/molecule. This surface concentration substantially
exceeds monolayer coverage of the interface and emphasizes film
properties associated with compression past collapse. Representative
surface excess -A isotherms for DPPC/SP-B films at apoprotein
contents of 0, 0.1, 0.25, 0.5, and 0.75% by weight relative to
phospholipid are shown in Fig. 5. As SP-B
content is raised, there is a successively larger shift to the right in
the second and/or seventh compression curves on these representative
isotherms, indicative of increased film respreading. Respreading
calculations for DPPC/SP-B and PPL/SP-B films based on collapse plateau
ratios from multiple isotherms at different apoprotein contents are
given in Table 1. PPL/SP-B films had
significantly better respreading than corresponding DPPC/SP-B films at
fixed apoprotein content, reflecting the much better respreading of the
complete mix of lung surfactant phospholipids relative to DPPC alone.
Very low SP-B contents of
0.1% by weight improved respreading in
films with DPPC, whereas effects on PPL film respreading were small.
However, all phospholipid/SP-B films exhibited a similar conceptual
pattern of increased dynamic respreading as SP-B content was
incrementally increased to 0.75% (Table 1).
|
|
Physiological activity experiments addressed the effects of tracheally
instilled SL/SP-B mixtures on P-V deflation mechanics in excised,
lavaged rat lungs. The lipid mixture in these excised lung studies had
a broad distribution of lipid components superficially related to those
in lavaged lung surfactant (SL = 40:40:10:5:2.5:2.5 DPPC/egg
PC/egg PG/egg PI/egg PE/Sph + 5% cholesterol). As found in
biophysical studies, the activity of SL/SP-B mixtures in improving surfactant-deficient P-V deflation mechanics increased
as apoprotein content was raised from 0.1 to 0.75% (Fig. 6, Table 2). Small but
measurable improvements in surfactant-deficient mechanics were present
for SL/SP-B mixtures with low apoprotein contents of 0.1-0.2% by
weight relative to phospholipid. SL/SP-B (0.3% by weight) had a
significantly increased activity in improving surfactant-deficient
mechanics, and activity at low transpulmonary pressures was increased
further in SL/SP-B (0.5%) and SL/SP-B (0.75%) mixtures. The activity
of SL/SP-B (0.75% by weight) in lavaged excised rat lungs approached
but did not fully equal that of CLSE (Fig. 6, Table 2).
|
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
This study has examined the content-dependent effects of
surfactant protein SP-B on the adsorption, dynamic surface behavior, and pulmonary mechanical activity of lipids. Biophysical and
physiological studies on three different lipid/SP-B mixtures were
consistent in demonstrating substantial activity differences as a
function of apoprotein content. At fixed SP-B content, adsorption and
dynamic surface tension lowering for the mixtures studied were
generally ordered as PPL/SP-B SL/SP-B > DPPC/SP-B.
However, all mixtures gave similar patterns of surface activity changes
with SP-B content. Very low SP-B contents
0.1% by weight had a
measurable effect in increasing the adsorption, dynamic surface tension
lowering, and film respreading of DPPC, SL, and/or column-purified lung surfactant phospholipids (Figs. 1-4, Table 1). However, surface activity successively increased as SP-B content was incrementally raised to 0.75% by weight relative to phospholipid. The adsorption and
dynamic surface tension lowering of PPL/SP-B (0.75%) were only
slightly less than CLSE, a highly active surfactant extract containing the complete mix of lipids and hydrophobic proteins from
lavaged calf lung surfactant (18, 21, 33, 34, 38) (Figs.
1C and 4). Mixtures of SL/SP-B (0.75%) and DPPC/SP-B
(0.75%) also adsorbed rapidly and reached low minimum surface tensions <1 mN/m during dynamic cycling at a low phospholipid concentration of
1 mg/ml in pulsating bubble studies (Figs. 1-3). Mixtures of PPL,
SL, or DPPC with 0.5% SP-B had reduced rates of adsorption and dynamic
surface tension lowering, but did reach minimum surface tensions <1
mN/m during prolonged cycling (Figs. 1-4).
Wilhelmy balance experiments on dynamic respreading in cycled
interfacial films also displayed the content-dependent effects of SP-B
in mixtures with phospholipids (Fig. 5, Table 1). Variations in
respreading as a function of SP-B content in interfacial films at room
temperature in the Wilhelmy balance were conceptually similar to those
in adsorption and pulsating bubble studies on surfactant dispersions at
37°C. Even very low SP-B contents 0.1% by weight impacted the
respreading of DPPC, and this film property then improved further as
levels of SP-B were increased from 0.1 to 0.75% (Table 1). Previous
studies have also documented the very poor respreading of pure DPPC in
cycled surface films (e.g., Refs. 37, 52),
which may make the effects of low levels of SP-B more apparent. The
complete mix of rigid and fluid surfactant phospholipids in PPL has
much higher film respreading than DPPC (57). Despite this,
low SP-B contents of 0.1-0.25% by weight also generated
measurable respreading improvements in films with PPL, with larger
increases as apoprotein content was raised further (Table 1).
The content-dependent activity of SP-B was also apparent in physiological measurements on the effects of instilled SL/SP-B mixtures in excised, lavaged rat lungs. The ability of SL/SP-B mixtures to improve surfactant-deficient P-V deflation mechanics increased as SP-B content increased from 0.1 to 0.75% by weight (Fig. 6, Table 2). SL/SP-B mixtures with apoprotein contents of 0.75% had very substantial mechanical activity, although the degree of P-V restoration did not fully equal that of CLSE. Mixtures of SL/SP-B (0.5 and 0.3%) also had significant activity in the excised lungs. The mechanical activity of SL/SP-B (0.3%) appeared to be greater relative to SL/SP-B (0.2%) than found in adsorption and dynamic surface activity studies on corresponding SL/SP-B mixtures (Fig. 6 vs. Figs. 1B and 3). However, physiological data were consistent with biophysical findings in showing an overall pattern of increasing activity for SL/SP-B mixtures as apoprotein content increased. The excised rat lung model in our experiments has previously been used with success to correlate the pulmonary activity of lung surfactants with their surface activity and inhibition (e.g., 17, 21, 22, 38). The rat lung model has also been shown in multiple studies to respond to the instillation of whole and extracted lung surfactant materials that improve in vivo pulmonary function in other animal models of surfactant deficiency and dysfunction (see Ref. 34 for review).
The physiological range of SP-B contents in endogenous lung surfactant
from animals of different species and age is not known precisely. CLSE
used in comparison studies here has been reported to have a content of
SP-B of ~0.9% by weight relative to phospholipid (39).
Our data indicate that lower SP-B contents of 0.75% (and to a lesser
extent 0.5%) also generate significant improvements in the adsorption,
dynamic surface activity, and physiological activity of lipids. If
molecular weights of 750 and 7,500 are used for phospholipids and
monomeric SP-B, respectively, a weight content of 0.5% SP-B relative
to phospholipid is equivalent to a molar ratio of 5 × 104. This indicates that SP-B significantly affects
phospholipid activity when one molecule of peptide monomer is present
among 2,000 phospholipid molecules. If dimer SP-B rather than monomer SP-B is assumed to be the active functional form, the number of phospholipid molecules per molecule of active protein is twice as
large. The ability of SP-B to enhance the surface activity of
phospholipids at such molecular ratios is striking and is consistent with prior research indicating the crucial functional relevance of this
surfactant apoprotein in endogenous and exogenous lung surfactants.
Although both of the hydrophobic lung surfactant proteins are known to
enhance phospholipid activity, multiple studies indicate that SP-B is
more effective than SP-C on a weight and molar basis (13, 25, 34,
40, 41, 44, 46, 48, 56, 58). SP-B has been shown to be more
active than SP-C in increasing both the adsorption and dynamic surface
tension lowering of phospholipids (13, 44, 46, 48, 56,
58). The improved adsorption of mixtures of phospholipids with
SP-B is consistent with the finding that this apoprotein has a fourfold
higher capacity for binding lipid vesicles to interfacial films on a
weight basis compared with SP-C (40, 41). Mixtures of
phospholipids with SP-B vs. SP-C also have an improved ability to
resist inhibition by serum albumin (48, 56). These
biophysical findings correlate directly with physiological activity
studies. Exogenous surfactants containing lipids combined with SP-B
have been found to give greater improvements in pulmonary mechanics and
function in animals than corresponding mixtures of lipids with SP-C
(45). Supplementation with SP-B or related synthetic
peptides has also been shown to improve the surface and physiological
activity of the clinical exogenous surfactant Survanta, which contains
SP-C but has only very low levels of SP-B (28, 39, 55).
The high surface and physiological activity of SP-B vs. SP-C is
consistent with the lethal nature of congenital SP-B deficiency in
humans (14, 19, 31, 32). Lethal respiratory failure also
occurs in "knockout" mice lacking the SP-B gene (9),
and compliance abnormalities exist even in mice that are SP-B (+/)
heterozygotes (8, 50).
Although not a primary focus of study, our experiments did address the interactions of SP-B with different phospholipids. The finding that mixtures of DPPC/SP-B had substantial surface and physiological activity, which increased with SP-B content, indicates the ability of this amphipathic apoprotein to interact strongly with disaturated phosphatidylcholine molecules. However, the fact that PPL/SP-B mixtures consistently had better surface activity suggests that the complete mix of phospholipids in lung surfactant is important in interacting with SP-B. This mix of lung surfactant phospholipids includes unsaturated as well as saturated phosphatidylcholines plus multiple anionic phospholipids (34). The detailed roles and importance of specific phospholipid molecules in interacting with SP-B require more comprehensive investigation in future research.
The current study focused on defining quantitative improvements in activity associated with different contents of SP-B in dispersions and films and did not address functional molecular biophysical mechanisms. Substantial prior research has investigated the molecular biophysical interactions of SP-B with phospholipids. SP-B is known to increase phospholipid aggregation, disrupt and fuse phospholipid bilayers and vesicles, and promote phospholipid insertion into surface films (6, 12, 40-42). Human SP-B monomer contains not only hydrophobic amino acids but also polar residues, including 10 basic Arg/Lys residues that are positively charged at neutral pH. This may facilitate specific interactions of SP-B with anionic phospholipids as well as zwitterionic phosphatidylcholines in lung surfactants. Due to its overall amphipathic structure, SP-B likely occupies a relatively peripheral position in phospholipid bilayers where it can interact with both head groups and hydrophobic chains (1, 10, 40, 42, 43, 53). SP-B can order the head-group region of lipid bilayers and increase the gel-to-liquid crystal transition temperatures of fluid phospholipids (1, 2, 30, 53, 54). SP-B also broadens phase transition width, indicating an ability to disrupt or reduce order in at least a portion of the bilayer (1, 2, 23, 24, 30, 43). The extensive molecular biophysical interactions between SP-B and phospholipids support a crucial role for this apoprotein in surfactant biophysical function consistent with the activity findings here.
In summary, this study shows the striking content-dependent impact of
SP-B on the surface and physiological activity of lipids. Even low SP-B
contents of 0.1% by weight had measurable effects in increasing
the adsorption, dynamic surface tension lowering, and/or film
respreading of DPPC, mixed synthetic lipids, and column-purified lung
surfactant phospholipids. The magnitude of surface activity improvements associated with SP-B increased significantly as apoprotein content was incrementally raised to 0.75% by weight in phospholipid mixtures. Physiological studies in lavaged excised rat lungs also showed that SP-B had content-dependent activity in improving the ability of instilled lipid-SP-B mixtures (0.1-0.75%) to reverse surfactant-deficient P-V deflation mechanics. Activity results were
consistent with the ability of SP-B to influence the biophysical function of phospholipids in a molar ratio of 1:2,000 in endogenous and
exogenous lung surfactants.
![]() |
ACKNOWLEDGEMENTS |
---|
This work was supported in part by National Heart, Lung, and Blood Institute Grant HL-56176.
![]() |
FOOTNOTES |
---|
Address for reprint requests and other correspondence: R. H. Notter, Dept. of Pediatrics (Neonatology, Box 850), Univ. of Rochester School of Medicine, 601 Elmwood Ave., Rochester, NY 14642.
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
10.1152/ajplung.00431.2001
Received 2 November 2001; accepted in final form 18 March 2002.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Baatz, JE,
Elledge B,
and
Whitsett JA.
Surfactant protein SP B induces ordering at the surface of model membrane bilayers.
Biochemistry
29:
6714-6720,
1990[ISI][Medline].
2.
Baatz, JE,
Sarin V,
Absolom DR,
Baxter C,
and
Whitsett JA.
Effects of surfactant associated protein SP B synthetic analogues on the structure and surface activity of model membrane bilayers.
Chem Phys Lipids
60:
163-178,
1991[ISI][Medline].
3.
Bermel, MS,
McBride JT,
and
Notter RH.
Lavaged excised rat lungs as a model of surfactant deficiency.
Lung
162:
99-113,
1984[ISI][Medline].
4.
Bernhard, W,
Mottaghian J,
Gebert A,
Rau GA,
von der Hardt H,
and
Poets CF.
Commercial versus native surfactants: surface activity, molecular components, and the effects of calcium.
Am J Respir Crit Care Med
162:
1524-1533,
2000
5.
Bligh, EG,
and
Dyer WJ.
A rapid method of total lipid extraction and purification.
Can J Biochem Physiol
37:
911-917,
1959[ISI].
6.
Chang, R,
Nir S,
and
Poulain FR.
Analysis of binding and membrane destabilization of phospholipid membranes by surfactant apoprotein B.
Biochim Biophys Acta
1371:
254-264,
1998[ISI][Medline].
7.
Chen, PS,
Toribara TY,
and
Huber W.
Microdetermination of phosphorus.
Anal Chem
28:
1756-1758,
1956[ISI].
8.
Clark, JC,
Weaver TE,
Iwamoto HS,
Ikegami M,
Jobe AH,
Hull WM,
and
Whitsett JA.
Decreased lung compliance and air trapping in heterozygous SP-B-deficient mice.
Am J Respir Cell Mol Biol
16:
46-52,
1997[Abstract].
9.
Clark, JC,
Wert SB,
Bachurski CJ,
Stahlman MT,
Stripp BR,
Weaver TE,
and
Whitsett JA.
Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice.
Proc Natl Acad Sci USA
92:
7794-7798,
1995[Abstract].
10.
Cochrane, CG,
and
Revak SD.
Pulmonary surfactant protein B (SP-B): structure-function relationships.
Science
254:
566-568,
1991[ISI][Medline].
11.
Creuwels, LAJM,
van Golde LMG,
and
Haagsman HP.
The pulmonary surfactant system: biochemical and clinical aspects.
Lung
175:
1-39,
1997[ISI][Medline].
12.
Creuwels, LAJM,
van Golde LMG,
and
Haagsman HP.
Surfactant protein B: effects on lipid domain formation and intermembrane lipid flow.
Biochim Biophys Acta
1285:
1-8,
1996[ISI][Medline].
13.
Curstedt, T,
Jornvall H,
Robertson B,
Bergman T,
and
Berggren P.
Two hydrophobic low-molecular-mass protein fractions of pulmonary surfactant: characterization and biophysical activity.
Eur J Biochem
168:
255-262,
1987[Abstract].
14.
DeMello, DE,
Nogee LM,
Heyman S,
Krous HF,
Hussain M,
Merritt TA,
Hsueh W,
Haas JE,
Heidelberger K,
Schumacher R,
and
Colten HR.
Molecular and phenotypic variability in the congenital alveolar proteinosis syndrome associated with inherited surfactant protein B deficiency.
J Pediatr
125:
43-50,
1994[ISI][Medline].
15.
Enhorning, G.
Pulsating bubble technique for evaluation of pulmonary surfactant.
J Appl Physiol
43:
198-203,
1977
16.
Hall, SB,
Bermel MS,
Ko YT,
Palmer HJ,
Enhorning GA,
and
Notter RH.
Approximations in the measurement of surface tension with the oscillating bubble surfactometer.
J Appl Physiol
75:
468-477,
1993[Abstract].
17.
Hall, SB,
Lu ZR,
Venkitaraman AR,
Hyde RW,
and
Notter RH.
Inhibition of pulmonary surfactant by oleic acid: mechanisms and characteristics.
J Appl Physiol
72:
1708-1716,
1992
18.
Hall, SB,
Wang Z,
and
Notter RH.
Separation of subfractions of the hydrophobic components of calf lung surfactant.
J Lipid Res
35:
1386-1394,
1994[Abstract].
19.
Hamvas, A,
Cole FS,
deMello DE,
Moxley M,
Whitsett JA,
Colten HR,
and
Nogee LM.
Surfactant protein B deficiency: antenatal diagnosis and prospective treatment with surfactant replacement.
J Pediatr
125:
356-361,
1994[ISI][Medline].
20.
Hawgood, S.
Surfactant: composition, structure, and metabolism.
In: The Lung: Scientific Foundations (2nd ed.), edited by Crystal RG,
West JB,
Weibel ER,
and Barnes PJ.. Philadelphia: Lippincott-Raven, 1997, p. 557-571.
21.
Holm, BA,
and
Notter RH.
Effects of hemoglobin and cell membrane lipids on pulmonary surfactant activity.
J Appl Physiol
63:
1434-1442,
1987
22.
Holm, BA,
Venkitaraman AR,
Enhorning G,
and
Notter RH.
Biophysical inhibition of synthetic lung surfactants.
Chem Phys Lipids
52:
243-250,
1990[ISI][Medline].
23.
Horowitz, AD.
Exclusion of SP-C, but not SP-B, by gel phase palmitoyl lipids.
Chem Phys Lipids
76:
27-39,
1995[ISI][Medline].
24.
Horowitz, AD,
Elledge B,
Whitsett JA,
and
Baatz JE.
Effects of lung surfactant proteolipid SP-C on the organization of model membrane lipids: a fluorescence study.
Biochim Biophys Acta
107:
44-54,
1992.
25.
Johansson, J,
Gustafsson M,
Zaltash S,
Robertson B,
and
Curstedt T.
Synthetic surfactant protein analogs.
Biol Neonate
74 Suppl:
9-14,
1998[ISI][Medline].
26.
Kaplin, RS,
and
Pedersen PL.
Sensitive protein assay in the presence of high levels of lipid.
Anal Biochem
150:
97-104,
1989.
27.
Lowry, OH,
Rosebrough NJ,
Farr AL,
and
Randall RJ.
Protein measurement with the Folin phenol reagent.
J Biol Chem
132:
265-275,
1951.
28.
Mizuno, K,
Ikegami M,
Chen C-M,
Ueda T,
and
Jobe AH.
Surfactant protein-B supplementation improves in vivo function of a modified natural surfactant.
Pediatr Res
37:
271-276,
1995[Abstract].
29.
Morrissey, JH.
Silver stain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity.
Anal Biochem
117:
307-310,
1981[ISI][Medline].
30.
Morrow, MR,
Pérez-Gil J,
Simatos GA,
Boland C,
Stewart J,
Absolom D,
Sarin V,
and
Keough KMW
Pulmonary surfactant-associated protein SP-B has little effect on acyl chains in dipalmitoylphosphatidylcholine dispersions.
Biochemistry
32:
4397-4402,
1993[ISI][Medline].
31.
Nogee, LM,
deMello DE,
Dehner LP,
and
Colten HR.
Brief report: deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis.
N Engl J Med
328:
406-410,
1993
32.
Nogee, LM,
Garnier G,
Dietz HC,
Singer L,
Murphy AM,
deMello DE,
and
Colten HR.
A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds.
J Clin Invest
93:
1860-1863,
1994[ISI][Medline].
33.
Notter, R,
Taubold R,
and
Finkelstein J.
Comparative adsorption of natural lung surfactant, extracted phospholipids, and synthetic phospholipid mixtures.
Chem Phys Lipids
33:
67-80,
1983[ISI][Medline].
34.
Notter, RH.
Lung Surfactants: Basic Science and Clinical Applications. New York: Dekker, 2000.
35.
Notter, RH,
Smith S,
Taubold RD,
and
Finkelstein JN.
Path dependence of adsorption behavior of mixtures containing dipalmitoyl phosphatidylcholine.
Pediatr Res
16:
515-519,
1982[Abstract].
36.
Notter, RH,
Tabak SA,
Holcomb S,
and
Mavis RD.
Post-collapse dynamic surface pressure relaxation in binary surface films containing dipalmitoyl phosphatidylcholine.
J Colloid Interface Sci
74:
370-377,
1980[ISI].
37.
Notter, RH,
Tabak SA,
and
Mavis RD.
Surface properties of binary mixtures of some pulmonary surfactant components.
J Lipid Res
21:
10-22,
1980[Abstract].
38.
Notter, RH,
and
Wang Z.
Pulmonary surfactant: physical chemistry, physiology and replacement.
Rev Chem Eng
13:
1-118,
1997[ISI].
39.
Notter, RH,
Wang Z,
Egan EA,
and
Holm BA.
Component-specific surface and physiological activity in bovine-derived lung surfactants.
Chem Phys Lipids
114:
21-34,
2002[ISI][Medline].
40.
Oosterlaken-Dijksterhuis, MA,
Haagsman HP,
van Golde LM,
and
Demel RA.
Characterization of lipid insertion into monomolecular layers mediated by lung surfactant proteins SP-B and SP-C.
Biochemistry
30:
10965-10971,
1991[ISI][Medline].
41.
Oosterlaken-Dijksterhuis, MA,
Haagsman HP,
van Golde LM,
and
Demel RA.
Interaction of lipid vesicles with monomolecular layers containing lung surfactant proteins SP-B or SP-C.
Biochemistry
30:
8276-8281,
1991[ISI][Medline].
42.
Oosterlaken-Dijksterhuis, MA,
van Eijk M,
van Golde LMG,
and
Haagsman HP.
Lipid mixing is mediated by the hydrophobic surfactant protein SP-B but not by SP-C.
Biochim Biophys Acta
1110:
45-50,
1992[ISI][Medline].
43.
Perez-Gil, J,
Casals C,
and
Marsh D.
Interactions of hydrophobic lung surfactant proteins SP-B and SP-C with dipalmitoylphosphatidylcholine and dipalmitoyl phosphatidylglycerol bilayers studies by electron spin resonance spectroscopy.
Biochemistry
34:
3964-3791,
1995[ISI][Medline].
44.
Revak, SD,
Merritt TA,
Degryse E,
Stefani L,
Courtney M,
Hallman M,
and
Cochrane CG.
The use of human low molecular weight (LMW) apoproteins in the reconstitution of surfactant biological activity.
J Clin Invest
81:
826-833,
1988[ISI][Medline].
45.
Rider, E,
Ikegami M,
Whitsett J,
Hull W,
Absolom D,
and
Jobe A.
Treatment responses to surfactants containing natural surfactant proteins in preterm rabbits.
Am Rev Respir Dis
147:
669-676,
1993[ISI][Medline].
46.
Sarin, VK,
Gupta S,
Leung TK,
Taylor VE,
Ohning BL,
Whitsett JA,
and
Fox JL.
Biophysical and biological activity of a synthetic 8.7 kDa hydrophobic pulmonary surfactant protein SP-B.
Proc Natl Acad Sci USA
87:
2633-2637,
1990[Abstract].
47.
Seeger, W,
Grube C,
Günther A,
and
Schmidt R.
Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations.
Eur Respir J
6:
971-977,
1993[Abstract].
48.
Seeger, W,
Günther A,
and
Thede C.
Differential sensitivity to fibrinogen inhibition of SP-C- vs. SP-B-based surfactants.
Am J Physiol Lung Cell Mol Physiol
262:
L286-L291,
1992
49.
Tabak, SA,
and
Notter RH.
A modified technique for dynamic surface pressure and relaxation measurements at the air-water interface.
Rev Sci Instrum
48:
1196-1201,
1977[ISI].
50.
Tokieda, K,
Whitsett JA,
Clark JC,
Weaver TE,
Ikeda K,
McConnell KB,
Jobe AH,
Ikegami M,
and
Iwamoto HS.
Pulmonary dysfunction in neonatal SP-B deficient mice.
Am J Physiol Lung Cell Mol Physiol
273:
L875-L882,
1997
51.
Touchstone, JC,
Chen JC,
and
Beaver KM.
Improved separation of phospholipids in thin-layer chromatography.
Lipids
15:
61-62,
1980[ISI].
52.
Turcotte, JG,
Sacco AM,
Steim JM,
Tabak SA,
and
Notter RH.
Chemical synthesis and surface properties of an analog of the pulmonary surfactant dipalmitoyl phosphatidylcholine analog.
Biochim Biophys Acta
488:
235-248,
1977[ISI][Medline].
53.
Vandenbussche, G,
Clercx A,
Clercx M,
Curstedt T,
Johansson J,
Jörnvall H,
and
Ruysschaert JM.
Secondary structure and orientation of the surfactant protein SP-B in a lipid environment. A Fourier transform infrared spectroscopy study.
Biochemistry
31:
9169-9176,
1992[ISI][Medline].
54.
Vincent, JS,
Revak SD,
Cochrane CD,
and
Levin IW.
Interactions of model human pulmonary surfactants with a mixed phospholipid bilayer assembly: Raman spectroscopic studies.
Biochemistry
32:
8228-8238,
1993[ISI][Medline].
55.
Walther, FJ,
Hernandez-Juviel J,
Bruni R,
and
Waring A.
Spiking Survanta with synthetic surfactant peptides improves oxygenation in surfactant-deficient rats.
Am J Respir Crit Care Med
156:
855-861,
1997
56.
Wang, Z,
Gurel O,
Baatz JE,
and
Notter RH.
Differential activity and lack of synergy of lung surfactant proteins SP-B and SP-C in surface-active interactions with phospholipids.
J Lipid Res
37:
1749-1760,
1996[Abstract].
57.
Wang, Z,
Hall SB,
and
Notter RH.
Dynamic surface activity of films of lung surfactant phospholipids, hydrophobic proteins, and neutral lipids.
J Lipid Res
36:
1283-1293,
1995[Abstract].
58.
Yu, SH,
and
Possmayer F.
Comparative studies on the biophysical activities of the low-molecular-weight hydrophobic proteins purified from bovine pulmonary surfactant.
Biochim Biophys Acta
961:
337-350,
1988[ISI][Medline].